COPENHAGEN, Jan 19, 2026, 21:15 CET — Trading wrapped up for the day.
- Shares of Novo Nordisk B dropped 2.8% on Monday, giving back part of last week’s rally
- Investors are zeroing in on early prescription data for the new oral form of Wegovy
- The next key date is Feb. 4, when the company will release its full-year results
Novo Nordisk shares slipped on Monday, giving back a portion of last week’s rally as investors weighed early demand data for the company’s new Wegovy weight-loss drug ahead of the trading week.
The Copenhagen-listed B shares fell 2.8%, ending the day at 378.15 Danish crowns after moving between 373.90 and 384.00 crowns. Around 4.7 million shares changed hands, according to Yahoo Finance. Yahoo Finance
This change matters because early prescription data in the coming weeks will be the main indicator for how Novo’s oral obesity drug is faring. It’s a significant move, expanding its GLP-1 franchise, a class of hormone-based drugs that curb appetite and lower blood sugar.
Sentiment is still fragile. Novo’s future depends on how quickly it can expand access and hold off Eli Lilly, which is also pushing an oral obesity drug.
In the U.S., Novo’s oral Wegovy reached nearly 3,100 prescriptions in the week ending Jan. 9, according to a Jan. 16 note from Leerink Partners citing IQVIA data, BioSpace reported Monday. Meanwhile, prescriptions for the wider Wegovy franchise slipped 11% week over week, as Lilly’s Zepbound saw a 3% rise.
Evercore ISI analyst Umer Raffat called the initial results “solid,” but noted that the weekly mix is still shifting, according to Investors.com over the weekend. The report also pointed to Lilly’s experimental oral option, orforglipron, which might reach the market as early as April. Investors.com
Novo is promoting the pill as a choice for patients who avoid injections, aiming to ease access amid ongoing supply constraints in the obesity-drug market. On Jan. 5, Novo Nordisk Inc said the once-daily pill is now “broadly available” across the U.S. PR Newswire
Early prescription numbers are still all over the place. Many tracking systems miss direct-to-consumer and telehealth orders, and insurers can quickly tighten coverage if demand spikes or rebate deals shift.
Traders will watch closely for updated prescription reads in the next session, trying to determine if Monday’s drop is merely a pause or the start of a pullback after last week’s rally.
Investors are gearing up for Novo’s full-year 2025 results, due Feb. 4. Attention will zero in on the 2026 sales forecast, along with any news on supply, pricing, and progress in their obesity pipeline. novonordisk.com
